Newsroom | 5088 results
Sorted by: Latest
-
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Inves...
-
Samenvatting: Tanner Pharma Group en Biodexa lanceren wereldwijd programma voor vroegtijdige toegang voor FAP-patiënten
CHARLOTTE, N.C. & CARDIFF, Verenigd Koninkrijk--(BUSINESS WIRE)--Tanner Pharma Group, een wereldwijde aanbieder van oplossingen voor de toegang tot gespecialiseerde geneesmiddelen, en Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), een biofarmaceutisch bedrijf in de klinische fase dat innovatieve producten voor maag-darmkanker ontwikkelt, hebben een strategisch partnerschap aangekondigd. Het doel is om patiënten met familiale adenomateuze polyposis (FAP) wereldwijd toegang te bieden tot eRapa via e...
-
Riassunto: Tanner Pharma Group e Biodexa lanciano il programma globale di accesso anticipato per i pazienti affetti da FAP
CHARLOTTE, North Carolina e CARDIFF, Regno Unito--(BUSINESS WIRE)--Tanner Pharma Group, fornitore globale di soluzioni di accesso a medicinali specifici e Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), un'azienda biofarmaceutica di fase clinica che sviluppa prodotti innovativi per tumori gastrointestinali, hanno annunciato una partnership strategica per consentire l'accesso globale a eRapa per i pazienti affetti da poliposi adenomatosa familiare (FAP) tramite un programma di accesso anticipato/per...
-
Resumen: Tanner Pharma Group y Biodexa lanzan un programa de acceso anticipado global para pacientes de poliposis adenomatosa familiar
CHARLOTTE (Carolina del Norte) y CARDIFF (Reino Unido)--(BUSINESS WIRE)--Tanner Pharma Group, proveedor global de soluciones de acceso a medicina especializada, y Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), empresa biofarmacéutica de fase clínica que desarrolla productos innovadores para tipos de cáncer gastrointestinales, anunciaron una alianza estratégica para posibilitar el acceso global a eRapa para pacientes con poliposis adenomatosa familiar (PAF) a través de un programa de acceso anticip...
-
Tanner Pharma Group et Biodexa lancent un programme mondial d’accès anticipé destiné aux patients atteints de polypose adénomateuse familiale
CHARLOTTE, Caroline du Nord & CARDIFF, Royaume-Uni--(BUSINESS WIRE)--Tanner Pharma Group, un fournisseur mondial de solutions d’accès aux médicaments spécialisés, et Biodexa Pharmaceuticals PLC (Nasdaq : BDRX), une société biopharmaceutique de stade clinique qui développe des produits innovants pour le traitement des cancers gastro-intestinaux, ont annoncé un partenariat stratégique visant à permettre l’accès mondial à eRapa pour les patients atteints de polypose adénomateuse familiale (PAF) da...
-
Tanner Pharma Group und Biodexa starten globales Early-Access-Programm für FAP-Patienten
CHARLOTTE, North Carolina, und CARDIFF, Vereinigtes Königreich--(BUSINESS WIRE)--Tanner Pharma Group, ein globaler Anbieter von Zugangslösungen für Spezialmedikamente, und Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das innovative Produkte für die Behandlung von gastrointestinalen Krebserkrankungen entwickelt, gaben jetzt eine strategische Partnerschaft bekannt, durch die ein globaler Zugang zu eRapa für Patienten mit familiärer adeno...
-
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients
CHARLOTTE, N.C. & CARDIFF, United Kingdom--(BUSINESS WIRE)--Tanner Pharma and Biodexa have partnered to enable global access to eRapa for FAP patients through an Early Access Program....
-
Insulet Appoints Mike Panos as Chief Commercial Officer
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Mike Panos as Chief Commercial Officer...
-
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology...
-
Mochi Health and Livelong Women's Health Summit Partner to Advance Women's Metabolic Health
SAN FRANCISCO--(BUSINESS WIRE)--Mochi Health, the telehealth marketplace transforming how patients access affordable, transparent care, announced its participation as a Premiere Sponsor of the Livelong Women's Health Summit, taking place April 17-18 in San Francisco. Founder and CEO Myra Ahmad, M.D will represent the company as a featured speaker and roundtable host. Myra will join a panel of leading physicians for a session titled "The Ozempic Era: What GLP-1 Medications Mean for Women's Metab...